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a b s t r a c t
Stroke is the main cause of motoric and neuropsychological disability in adults. Recent
advances in research into the role of the brain-derived neurotrophic factor in neuroplas-
ticity, neuroprotection and neurogenesis might provide important information for the
development of new poststroke-rehabilitation strategies. It plays a role as a mediator in
motor learning and rehabilitation after stroke. Concentrations of BDNF are lower in acute
ischemic-stroke patients compared to controls. Lower levels of BDNF are correlated with an
increased risk of stroke, worse functional outcomes and higher mortality. BDNF signalling is
dependent on the genetic variation which could affect an individual's response to recovery
after stroke.
Several single nucleotide polymorphisms of the BDNF gene have been studied with
regard to stroke patients, but most papers analyse the rs6265 which results in a change from
valine to methionine in the precursor protein. Subsequently a reduction in BDNF activity is
observed. There are studies indicating the role of this polymorphism in brain plasticity,
functional and morphological changes in the brain. It may affect the risk of ischemic stroke,
post-stroke outcomes and the efﬁcacy of the rehabilitation process within physical exercise
and transcranial magnetic stimulation. There is a consistent trend of Met alleles' being
connected with worse outcomes and prognoses after stroke. However, there is no satisfac-
tory data conﬁrming the importance of Met allele in stroke epidemiology and the post-stroke
rehabilitation process. We present the current data on the role of BDNF and polymorphisms
of the BDNF gene in stroke patients, concentrating on human studies.
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Stroke is the main cause of motoric disability in adults,
especially after 60 years of age. There is speciﬁc treatment for
stroke, such as the recombinant tissue-plasminogen activator,
which decreases the risk of motoric impairment, but its
efﬁcacy is still not fully satisfactory. New studies have been
published to search for neuroprotection and neuroplasticity
in cerebrovascular disorders. Moreover, motoric, speech and
cognitive rehabilitation relates to signiﬁcant aspects of
secondary-stroke management. The brain-derived neuro-
trophic factor (BDNF) is part of the neurotrophin family of
growth factors, such as the nerve-growth factors (NGF)
neurotrophins 3 and 4 (NT-3, NT-4) [1]. They are responsible
for enhancing progenitor-cell proliferation and differentiation,
cell growth, regeneration processes, neuronal survival, synap-
tic regulation and remodelling, the regulation of plasticity, and
repair and connectivity in the brain [2,3]. The effects of
neurotrophins are mediated by a family of speciﬁc transmem-
brane tyrosine-kinase receptors, of which TrkB is the primary
signal-transduction receptor for BDNF [3].
Recent advances in research into the role of BDNF in
neuroplasticity, neuroprotection and neurogenesis might
provide important information for the development of new
poststroke rehabilitation strategies. It plays a role as a mediator
in motor learning and rehabilitation after stroke. This protein is
involved in a number of brain functions, including neuroplastic
changes which underly motor learning. It exerts its effects on
neuroplasticity by facilitating long-term potentiation and a
long-lasting increase in the strength of the connection between
the two neurons which are repeatedly activated together.
Dendritic growth and remodelling are also promoted [4]. This
trophic factor has direct effects on oligodendroglia, promoting
the proliferation and differentiation of oligodendrocyte-
precursor cells (OPC) and myelination [5]. It promotes prosta-
cyclin biosynthesis in cerebral arteries [6].
Unlike other growth factors, BDNF is secreted in the CNS
(Central Nervous System) throughout both constitutive and
activity-dependent pathways. BDNF production is boosted by
activities such as learning, physical exercise, sensory stimu-
lation and motor-cortex activation [7]. The 32 kDa pro form
(proBDNF) is rapidly cleaved to the mature form after
secretion. This activity-dependent secretion is crucial for
the role of BDNF in promoting neuroplasticity in circuits
activated in response to experience [8,9].
BDNF plays an essential role in the integration and
optimisation of behavioural and metabolic responses to
environments with limited energy resources and intense
‘‘competition’’. In particular, BDNF signalling mediates adap-
tive responses in the central, autonomic, and peripheral
nervous systems from exercise and dietary-energy restriction
(DER). In the hypothalamus, BDNF inhibits food intake and
increases energy expenditure. By promoting synaptic plastici-
ty and neurogenesis in the hippocampus, BDNF mediates
exercise- and DER-induced improvements in cognitive func-
tion and neuroprotection. It also has the ability to regulate the
peripheral-energy metabolism [10].
Besides the potential clinical use of BDNF in stroke patients,
there are also reports of signiﬁcant correlations between itslevel in autoimmune and neurodegeneration disorders. The
conclusions reached in such studies can be used for scientiﬁc
investigations into stroke. The level of circulating BDNF
compared to healthy controls decreases, even at the early
stages of multiple sclerosis (MS), and it is associated negatively
with neurological impairment. This level is increased by
immunomodulating treatment with the interferone-beta 1b
[11,12]. The concentrations of BDNF are connected with
selected factors (cognitive impairment, low educational level,
advanced age) in Alzheimer's disease, and in patients with
mild cognitive impairment [13]. In amyotrophic lateral
sclerosis patients there were no beneﬁcial effects within the
primary endpoints (survival, retardation/loss of pulmonary
function) of BDNF administration, neither in the subcutaneous
injections nor in the intrathecal infusions used in various
doses in 9-months follow-ups. In a subgroup of patients with
respiratory impairment, and those who had developed
secondary altered-bowel function, the results showed statisti-
cally signiﬁcant beneﬁts [14,15]. No effect of BDNF intrathecal
administration on the functions of the autonomic sympathetic
or the parasympathetic system was observed in 9-months
follow-ups [16].
The therapeutic effect of BDNF administration on stroke
patients needs further investigations, including the potential
effect of improving the drug-delivery system throughout the
brain–blood barrier (BBB) by nano-particles, or by optimising
the pharmacokinetics of BDNF [17]. Previous studies of BDNF
administration in stroke involved only experimental or animal
models [17–19].
2. BDNF concentrations and stroke
There is occurring an emerging role of BDNF in cardiovascular-
risk factors and disorders, especially in ischaemic-stroke
patients. Lower plasma BDNF levels in physically active
men were associated with a higher atherogenic index (TC/
HDL), and higher levels of hsCRP and oxLDL. Increased levels of
circulating BDNF were present in subjects with a high level of
cardio-respiratory ﬁtness, as reﬂected in VO2max in the
Åstrand–Rhyming bike test. BDNF interacts with oxidative
stress and inﬂammatory molecules, as its level can be raised
by the administration of atorvastatin for ischaemic stroke
[3,20]. The level of BDNF is associated with the occurrence of
delirium in intensive-care-unit patients, but not in individuals
with ischaemic stroke [21,22].
Concentrations of BDNF are lower in acute-ischaemic-
stroke patients compared with controls, but BDNF has not
been associated with 3-month outcomes. However, patients
with BDNF in the lowest tertile had an increased risk of
experiencing a poor outcome, at both the 2-year and 7-year
follow-ups [23]. Similar results were presented by other
authors, where the initial BDNF level at ischaemic-stroke
onset signiﬁcantly correlated with 3-months mortality, and
functional outcomes measured with the modiﬁed Rankin
Scale (mRS) – lower BDNF levels were connected with poor
outcomes and higher mortality [24,25].
In the Framingham Study during a median follow-up
lasting for 10 years, a lower BDNF level was associated with an
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CI: 1.09–2.00, p = 0.012). Moreover, subjects with a higher BDNF
level had less white-matter hyperintensity volume and better
visual memory, which might demonstrate the protective
properties of this protein [26]. Lower BDNF levels in a meta-
analysis published in year 2013 proved to be a signiﬁcant risk
factor in developing post-stroke depression [27]. Further
analyses conﬁrmed this conclusion [28].
BDNF plays an important role in stroke incidence and
outcome, but its use as a marker in the rehabilitation process
needs to be established. BDNF has a direct role in promoting
the migration of neuroblasts to ischaemic areas, and cells
migrating in the ischaemic striatum display higher explorato-
ry behaviour and longer stationary periods [29]. The systemic
level of BDNF increases for approximately 10–60 min following
aerobic exercise in humans, and the return to the baseline
level is achieved 1 h after such exercise [30]. Such observations
might suggest potential pathogenetic and clinical implications
for BDNF in the rehabilitation process. Two-week-long
combination therapy involving upper-limb rehabilitation
and repetitive transcranial magnetic stimulation (rTMS) in
post-stroke patients increased the level of the BDNF serum,
but not of the proBDNF serum. Moreover, the BDNF-serum
level did not correlate with motor-function improvement, but
the baseline proBDNF-serum level correlated negatively and
signiﬁcantly with improvement [31]. Despite the analyses of
functional outcomes in relation to BDNF levels, there are
limited data on the clinical value and potential use of BDNF as
a marker of the common neurorehabilitation process in stroke
patients in relation to methods, time of initiation, intensity,
and duration of rehabilitation.
Besides motoric rehabilitation, of note might be the
use of BDNF measurements in cognitive therapy, but also
limited studies have been performed in this ﬁeld. It has
been demonstrated that patients who underwent aerobic
training achieved cognitive improvement in relation to BDNF
level [32].
3. BDNF polymorphisms and stroke
BDNF signalling is dependent on the expression of genes. As a
result, genetic variation could affect an individual's response
to motor rehabilitation, training and motor recovery after
stroke. The BDNF protein is coded by the BDNF gene located on
the chromosome 11 (11p13) [4]. Several single nucleotide
polymorphis of BDNF gene have been described, but the most
promising as a clinically important polymorphism seems to be
the rs6265 SNP [33].
4. Rs6265 polymorphism of the BDNF gene
In approximately 30%–50% of the human population, there is a
single nucleotide polymorphism of the BDNF gene which
results in an amino-acid substitution of valine (Val) for
methionine (Met) at position 66 (val66met, rs6265, 196 G > A)
of the precursor peptide proBDNF [33]. The presence of the Met
allele results in a 25% reduction in the activity-dependent
secretion of BDNF in the CNS [9,34].The ﬁrst study to demonstrate the effect of the rs6265
polymorphism of the BDNF gene on activity-dependent
brain plasticity associated with movement was presented in
2006 [35].
There are not only functional, but also morphological,
changes in the brain, depending on the rs6265 SNP. The
authors detected a bilateral reduction in hippocampal grey-
matter volumes in Met-allele carriers compared with Val/Val.
In addition, a whole-brain analysis was performed on these
subjects, indicating reduced grey-matter volume in the lateral
convexity of the frontal lobes, with peak values bilaterally
encompassing the dorsolateral prefrontal cortex [36]. In a
small-sample-size study the Met allele was associated with an
11% reduction in the volume of hippocampal formation [37].
Besides the anatomical considerations, the functional effect of
rs6265 polymorphism of the BDNF gene can also be observed.
In a group of 42 ischaemic-stroke patients, decreased brain
activation was detected in the fMRI in Val/Met participants
compared to others [38]. Radiological correlates were also
found in MRI diffusion-tensor imaging (DTI) scans, indicating
an association between corticospinal degeneration, motor
function and 196 G > A BDNF gene polymorphism [39].
The role of the rs6265 SNP of the BDNF gene has also been
analysed in epidemiological and clinical studies in stroke
patients. An analysis was presented of ischaemic-stroke
occurrence in 206 stroke patients and 200 controls, but there
was no signiﬁcant association [40]. The risk of ischaemic
stroke was also analysed in 494 patients and 337 controls,
indicating a higher risk in Met/Met (AA) carriers of 196 G > A
polymorphism of the BDNF gene (OR 1.541; 95%CI: 1.034–2.298,
p = 0.028) [41].
Potential association between the rs6265 genotype and
neurological deﬁcit has been studied. 3-Months functional
outcomes measured with mRS were poor in Met-allele patients
[41]. Poor outcomes 2 weeks and 1 year after stroke were
observed in Val/Met-genotype patients [42]. Ischaemic-stroke
patients with Val/Met SNP had a median change in the NIHSS
(National Institute of Health Stroke Scale) score within 1
month after the stroke of only 4 points, compared to 5 points
amongst the rest, while no differences were found in the
analysis of changes in the NIHSS and mRS scores at the 3-
month interval [43]. There was also no impact on 30-day
outcomes, but at the 3-months observation period a positive
association was found [2,44].
Despite our prime interest in ischaemic stroke, there are
interesting results of studies on outcomes and cognition in
other types of stroke. There has also been a single analysis on
the role of the rs6265 SNP of BDNF gene in intracerebral and
subarachnoid haemorrhage patients. The Met carriers had
poor outcomes compared with the Val/Val group in the
assessment 3 months after the aneurysmal subarachnoid
haemorrhage (SAH) (OR 8.40; 95% CI: 1.60–44.00; p = 0.012) [45].
In patients assessed 1 year after the SAH with the use of the
neuropsychological test battery, the Val66Met polymorphism
of the BDNF gene was not associated with learning and
memory performance, but the Met carriers had poorer learning
and memory performance than Val/Val homozygotes in a
subgroup of patients without cerebral infarction [46]. In the
intracerebral haemorrhage patients, the Val/Val carriers
scored better in NIHSS on admission (14.23 versus 21.00,
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the onset. There was no impact on 30-day outcomes [2].
5. Neurorehabilitation and rs6265
polymorphism of the BDNF gene
The presented analyses were made irrespectively of the type of
neurorehabilitation, which to a great extent affects the
neurological outcome.
Several studies are available in which the authors pre-
sented rehabilitation characteristics, but generally no rela-
tionship between the BDNF genotype and the results was
found. In the mean follow-up lasting for 21 months, post-
stroke patients attending the upper-limb-rehabilitation pro-
gramme were assessed, depending on the SNP status. There
was no signiﬁcant effect of the BDNF genotype on motor
function at the baseline or following therapy. However, a
signiﬁcant interaction between the level of residual motor
function and the BDNF genotype was identiﬁed. The post-
therapy improvement was signiﬁcantly less for Met-allele
patients with moderate and high, but not low, motor function
[47]. In an analysis of 67 ischaemic-stroke patients no
correlation was detected between rs6265 SNP and both the
1- and 6-months motoric statuses after the inpatient rehabili-
tation [48]. In a study on the greater groups i.e. 600 ischaemic-
stroke patients and 600 controls with follow-up until 7 years,
there was again no association between the outcomes
measured at 3 months, 2 years and 7 years [49]. There was
also no signiﬁcant difference within the SNP regarding the
severity of the stroke and the functional disability in an
average period of 202 days after the stroke [40].
The results presented above do not overall provide
convincing data on the signiﬁcant role of rs6265 SNP of the
BDNF gene in epidemiology and the rehabilitation process for
stroke patients. In addition to physical therapy, the rTMS
(repetitive transcranial magnetic stimulation) proved to be
effective in the neurorehabilitation process in stroke patients.
The therapeutic results might be inﬂuenced by the BDNF
genotype, in both the acute and chronic period from the onset
[50]. The rTMS used 10 days after ischaemic stroke provoked
greater excitability over the unaffected hemisphere in patients
without the Met/Val genotype in a group of only 20 patients
[51]. A worse response to rTMS in 44 post-stroke patients was
also observed in Met-alle groups in comparison to the Val/Val
group [52]. At least 6 months after both ischaemic-stroke and
intracerebral haemorrhage, patients with Val/Met polymor-
phism were more likely to adapt to an aide, but this was tested
in only 27 subjects [53]. The rTMS performed 6 months after
the stroke onset in 22 patients with persistent paresis showed
differences in their motor-evoked potentials, depending on
their genotype status [50]. These potentially 'positive' studies
were performed on small sample sizes, so have limited
statistical weight and cannot be fully conclusive. There was
no correlation between genotype and rTMS use in the
rehabilitation of 26 ischaemic-stroke patients [54]. Even the
outcome of the combination therapy of upper-limb rehabilita-
tion and rTMS in post-stroke patients was not altered by any
rs6265 BDNF gene polymorphism [31].6. Neuropsychological dysfunctions and
rs6265 polymorphism of the BDNF gene
In addition to motoric impairment due to stroke, neuropsy-
chological dysfunctions such as cognitive impairment and
depression also signiﬁcantly affect social functioning. The
rs6265 SNP of BDNF gene variations can be clinically important
in cognitive dysfunctions. In the cohort of healthy subjects, the
Met/Met homozygotes had lower scores in episodic memory
measured by the Wechsler Memory Scale, and a revised
version (WMS-R) compared to the other two genotype groups
(Val/Val and Val/Met). The difference between the SNPs was
also evident in the blood-oxygenation-level dependent (BOLD)
functional MRI technique while performing the working-
memory task in the area of the hippocampus [34]. Moreover,
studies on post-stroke-dementia patients have been pre-
sented. In patients diagnosed with post-stroke dementia (PSD)
at the mean 6-months period, Val/Met carriers were at greater
risk of PSD (HR 2.280; 95% CI: 1.566–4.106, p = 0.006). However
the risk ratio was insigniﬁcant after adjusting demographic,
clinical, and vascular risk factors [55]. Therapy for cognitive
impairment in post-stroke patients employed with the use of
rTMS was not connected with any of the rs6265 SNP of the
BDNF gene, but only 40 patients were assessed for this [56]. The
Val-allele carriers had more cognitive impairment after IS
assessed on average 202 days after stroke, which is partially
inconsistent with the studies presented above, in which Val
allele had beneﬁcial effects on stroke patients [40]. The
psychopathological effect, such as post-stroke depression,
appeared not to be connected with this SNP status, but
only with the level of BDNF [57]. On the other hand, rs6265
SNP of the BDNF gene is the only one which has potential clinical
signiﬁcance in the risk of depression in stroke-free patients [58].
The potential role of Met allele in the neurorehabilitation
process presented above appears to be mainly explained by
the difference in the susceptibility to plasticity. This effect
takes place in the cortex and is less pronounced in Met
carriers, who have instead spared global-recovery potential.
Met carriers can beneﬁt from different rehabilitation strategies
from other genotypes, which should be considered and
analysed in further studies. Genotyping can gain clinical
signiﬁcance through the individualisation of motoric and
cognitive rehabilitation in stroke patients [7,59].
7. Other BDNF gene polymorphisms
The rs6265 SNP of the BDNF gene is a polymorphism of prime
interest, but there have been other SNPs tested as well, though
less frequently. There was a higher occurrence of the 270 CC
genotype of the BDNF gene in patients with haemorrhagic than
ischaemic stroke (96% versus 86%, p = 0.0495). None of the
determined polymorphisms had any impact on the 30-day
outcome in ischaemic and haemorrhagic strokes [2]. There
was no correlation between this genotype and rTMS use in the
rehabilitation of the 26 ischaemic-stroke patients [54].
A correlation was indicated between the rs11030119 SNP
of the BDNF gene and favourable outcomes measured 7 years
after the ischaemic stroke OR (0.6; 955CI: 0.42–0.86, p = 0.01) [49].
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rs2049046 polymorphisms of the BDNF gene on outcomes
measured at 3 months, 2 and 7 years after the ischaemic stroke
[49]. The latest SNP was connected with the risk of migraine
and migraine with aura, which is an established risk factor of
stroke [60].
8. Conclusions
BDNF and its polymorphisms appear to play an important role
in ischaemic-stroke patients, with special attention being paid
to motoric and neuropsychological rehabilitation. There are
reliable results indicating the evident connection between the
BDNF level and the risk of stroke, functional outcome and
mortality in stroke patients. We conclude that there are no
satisfactory data regarding the clinical utility of circulating
BDNF and the neurorehabilitation process in the acute phase
of stroke and in the post-stroke rehabilitation provided in
neurorehabilitation departments, where most stroke patients
should be referred in the event of no contra-indications. We
also propose that further studies should be continued on the
potentially beneﬁcial effects of BDNF administration in stroke
patients, as it can potentially penetrate the blood–brain-
barrier [61]. As long as there is no such treatment proven to be
safe and effective, other, non-invasive, methods of increasing
BDNF could be of importance. These include intensive, early
post-stroke rehabilitation, and probably rTMS.
Most of the available studies involve the rs6265 SNP of the
BDNF gene. There is a consistent trend that the Met allele is
connected with worse outcomes and prognoses after stroke,
but there is no convincing evidence of its role in effective
rehabilitation therapy for stroke epidemiology. However, this
SNP should be of interest in clinical studies, especially as Met-
inclusive allele is present in up to 66.2% of the population [62].
Despite the current pharmacotherapy for stroke, the rehabili-
tation process still remains an important and effective method
of decreasing motoric and cognitive disability. The present
data in human studies indicate weak or no signiﬁcance of
BDNF SNPs in post-stroke neurorehabilitation. However, the
potential role of SNPs in the identiﬁcation of special groups of
stroke patients in the rehabilitation process needs to be
established in further studies.
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